|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM134 |
Gene summary for TMEM134 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM134 | Gene ID | 80194 |
| Gene name | transmembrane protein 134 | |
| Gene Alias | TMEM134 | |
| Cytomap | 11q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H6X4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80194 | TMEM134 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.80e-07 | 3.79e-01 | -0.1808 |
| 80194 | TMEM134 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.01e-03 | 3.63e-01 | -0.0811 |
| 80194 | TMEM134 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.11e-05 | 2.73e-01 | -0.1954 |
| 80194 | TMEM134 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.50e-07 | 3.70e-01 | -0.1207 |
| 80194 | TMEM134 | HTA11_696_2000001011 | Human | Colorectum | AD | 8.18e-15 | 3.77e-01 | -0.1464 |
| 80194 | TMEM134 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.89e-10 | 2.77e-01 | -0.1001 |
| 80194 | TMEM134 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.06e-14 | 4.40e-01 | -0.059 |
| 80194 | TMEM134 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.22e-02 | 3.08e-01 | -0.0842 |
| 80194 | TMEM134 | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.88e-02 | 2.69e-01 | 0.0528 |
| 80194 | TMEM134 | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.12e-03 | 3.92e-01 | 0.0131 |
| 80194 | TMEM134 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.08e-04 | 2.90e-01 | 0.0338 |
| 80194 | TMEM134 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.51e-14 | 3.26e-01 | 0.0674 |
| 80194 | TMEM134 | HTA11_6818_2000001021 | Human | Colorectum | AD | 3.44e-07 | 3.49e-01 | 0.0588 |
| 80194 | TMEM134 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.45e-10 | 2.80e-01 | 0.294 |
| 80194 | TMEM134 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.08e-02 | 2.50e-01 | 0.281 |
| 80194 | TMEM134 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.14e-11 | 3.29e-01 | 0.3859 |
| 80194 | TMEM134 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.59e-11 | 2.55e-01 | 0.3005 |
| 80194 | TMEM134 | LZE2T | Human | Esophagus | ESCC | 1.14e-05 | 8.80e-01 | 0.082 |
| 80194 | TMEM134 | LZE4T | Human | Esophagus | ESCC | 1.11e-23 | 5.51e-01 | 0.0811 |
| 80194 | TMEM134 | LZE5T | Human | Esophagus | ESCC | 4.89e-04 | 3.42e-01 | 0.0514 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM134 | SNV | Missense_Mutation | c.469N>A | p.Phe157Ile | p.F157I | Q9H6X4 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM134 | SNV | Missense_Mutation | rs754993164 | c.308G>A | p.Arg103His | p.R103H | Q9H6X4 | protein_coding | tolerated(0.13) | probably_damaging(0.996) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM134 | SNV | Missense_Mutation | c.503N>C | p.Gly168Ala | p.G168A | Q9H6X4 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-51-6867-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |